Literature DB >> 15472290

Direct detection of rifampin-resistant mycobacterium tuberculosis in respiratory specimens by PCR-DNA sequencing.

W C Yam1, C M Tam, C C Leung, H L Tong, K H Chan, E T Y Leung, K C Wong, W W Yew, W H Seto, K Y Yuen, P L Ho.   

Abstract

This study evaluated the feasibility of a molecular strategy based on identification of Mycobacterium tuberculosis by IS6110 PCR or Cobas Amplicor PCR, and rpoB PCR-DNA sequencing of the 81-bp rifampin resistance determining region (RRDR) for direct detection of rifampin resistance in respiratory specimens. A collection of 2,138 respiratory specimens and 352 nonduplicate M. tuberculosis isolates (including 233 isolates from the evaluated respiratory specimens and an additional collection of 119 stored isolates) from Southern China was investigated. Using culture as the reference test, the overall diagnostic sensitivities of an acid-fast bacillus (AFB) smear, Cobas Amplicor PCR, IS6110 PCR were 54.5% (156 of 286), 86.7% (248 of 286), and 89.2% (255 of 286), respectively. The sensitivities of the rpoB PCR for the specimens with positive AFB smears and with positive PCR results in the IS6110 PCR and/or Cobas Amplicor PCR were 100% (156 of 156) and 92.3% (239 of 259), respectively. Of the 352 nonduplicate M. tuberculosis isolates, the agar proportion method for rifampin reported 39 resistant strains. Full agreement (352 of 352) was found with the agar proportion method and the genotype inferred from the rpoB DNA sequencing data for rifampin. Thirty-nine mutations of nine distinct kinds, eight point mutations, and one deletion within the RRDR were found in the 39 resistant strains. For the direct DNA sequencing performed on rpoB PCR-positive respiratory specimens, the concordance with the agar proportion method and the subsequent PCR-sequencing for the culture isolate was 100%. This strategy has potential application for direct and rapid diagnosis of rifampin-resistant M. tuberculosis in IS6110 PCR or Cobas Amplicor PCR-positive respiratory specimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472290      PMCID: PMC522342          DOI: 10.1128/JCM.42.10.4438-4443.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil.

Authors:  A R Valim; M L Rossetti; M O Ribeiro; A Zaha
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Trends in multidrug-resistant Mycobacterium tuberculosis in relation to sputum smear positivity in Hong Kong, 1989-1999.

Authors:  Kai Man Kam; Chi Wai Yip; Lai Wa Tse; Oi Chi Leung; Lai Ping Sin; Mei Yuk Chan; Wai Sum Wong
Journal:  Clin Infect Dis       Date:  2001-12-26       Impact factor: 9.079

3.  Multicenter study of a commercial, automated polymerase chain reaction system for the rapid detection of Mycobacterium tuberculosis in respiratory specimens in routine clinical practice.

Authors:  M Bogard; J Vincelette; R Antinozzi; R Alonso; T Fenner; J Schirm; D Aubert; C Gaudreau; E Sala; M J Ruiz-Serrano; H Petersen; L A Oostendorp; H Burkardt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-10       Impact factor: 3.267

4.  rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries.

Authors:  Lishi Qian; Chiyoji Abe; Tao-Ping Lin; Ming-Chih Yu; Sang-Nae Cho; Sumin Wang; James T Douglas
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis.

Authors:  F A Drobniewski; S A Watterson; S M Wilson; G S Harris
Journal:  J Med Microbiol       Date:  2000-03       Impact factor: 2.472

6.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  M A Espinal; A Laszlo; L Simonsen; F Boulahbal; S J Kim; A Reniero; S Hoffner; H L Rieder; N Binkin; C Dye; R Williams; M C Raviglione
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

7.  Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level.

Authors:  A Telenti; N Honoré; C Bernasconi; J March; A Ortega; B Heym; H E Takiff; S T Cole
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

8.  Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates.

Authors:  M Heep; B Brandstätter; U Rieger; N Lehn; E Richter; S Rüsch-Gerdes; S Niemann
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

9.  Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.

Authors:  L K Yuen; D Leslie; P J Coloe
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

10.  Determinants of drug-resistant tuberculosis: analysis of 11 countries.

Authors:  M A Espinal; K Laserson; M Camacho; Z Fusheng; S J Kim; R E Tlali; I Smith; P Suarez; M L Antunes; A G George; N Martin-Casabona; P Simelane; K Weyer; N Binkin; M C Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2001-10       Impact factor: 2.373

View more
  9 in total

1.  Occult drug resistance in tuberculosis: Emerging issues, upcoming challenges & possible solutions.

Authors:  Baijayantimala Mishra; Prasanta Raghab Mohapatra
Journal:  Indian J Med Res       Date:  2020-06       Impact factor: 2.375

2.  Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA.

Authors:  E T Y Leung; P L Ho; K Y Yuen; W L Woo; T H Lam; R Y Kao; W H Seto; W C Yam
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

3.  Rapid diagnosis of extensively drug-resistant tuberculosis by use of a reverse line blot hybridization assay.

Authors:  Kanchan Ajbani; Anjali Shetty; Ajita Mehta; Camilla Rodrigues
Journal:  J Clin Microbiol       Date:  2011-05-25       Impact factor: 5.948

4.  Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.

Authors:  Ricky W T Lau; Pak-Leung Ho; Richard Y T Kao; Wing-Wai Yew; Terrence C K Lau; Vincent C C Cheng; Kwok-Yung Yuen; Stephen K W Tsui; Xinchun Chen; Wing-Cheong Yam
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

5.  Rapid detection of rpoB mutations in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresis.

Authors:  Jun Li; Jiaojiao Xin; Liyuan Zhang; Longyan Jiang; Hongcui Cao; Lanjuan Li
Journal:  Int J Med Sci       Date:  2012-01-11       Impact factor: 3.738

6.  Application of next generation sequencing-based rapid detection platform for microbiological diagnosis and drug resistance prediction in acute lower respiratory infection.

Authors:  Lingshan Chao; Jihong Li; Ya'nan Zhang; Hao Pu; Xixin Yan
Journal:  Ann Transl Med       Date:  2020-12

7.  Spatial clustering and genetic diversity of Mycobacterium tuberculosis isolate among pulmonary tuberculosis suspected patients, Arsi Zone, Ethiopia.

Authors:  Ketema Tafess; Teresa Kisi Beyen; Sisay Girma; Asnakech Girma; Gilman Siu
Journal:  BMC Pulm Med       Date:  2021-06-30       Impact factor: 3.317

8.  Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong.

Authors:  Raphael C Y Chan; Mamie Hui; Edward W C Chan; T K Au; Miu L Chin; Chun K Yip; Carrie K W AuYeang; Christina Y L Yeung; Kai M Kam; Peter C W Yip; Augustine F B Cheng
Journal:  J Antimicrob Chemother       Date:  2007-03-14       Impact factor: 5.790

9.  Detection of mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains inhibiting wild type probe hybridization in the MTBDR plus assay by DNA sequencing directly from clinical specimens.

Authors:  Pallavi Sinha; G N Srivastava; Rajneesh Tripathi; Mukti Nath Mishra; Shampa Anupurba
Journal:  BMC Microbiol       Date:  2020-09-16       Impact factor: 3.605

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.